The 36-month beta value for ANAB is at -0.28. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANAB is 23.71M, and currently, shorts hold a 18.15% of that float. The average trading volume for ANAB on April 12, 2024 was 326.01K shares.
ANAB) stock’s latest price update
The stock price of AnaptysBio Inc (NASDAQ: ANAB) has jumped by 11.55 compared to previous close of 22.17. Despite this, the company has seen a gain of 16.10% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-09 that AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ANAB’s Market Performance
AnaptysBio Inc (ANAB) has seen a 16.10% rise in stock performance for the week, with a -5.10% decline in the past month and a 7.29% surge in the past quarter. The volatility ratio for the week is 6.05%, and the volatility levels for the past 30 days are at 5.93% for ANAB. The simple moving average for the past 20 days is 11.28% for ANAB’s stock, with a 23.50% simple moving average for the past 200 days.
Analysts’ Opinion of ANAB
Wedbush, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $34, previously predicting the price at $20. The rating they have provided for ANAB stocks is “Outperform” according to the report published on March 12th, 2024.
BTIG Research gave a rating of “Buy” to ANAB, setting the target price at $55 in the report published on February 26th of the current year.
ANAB Trading at 4.95% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.07% of loss for the given period.
Volatility was left at 5.93%, however, over the last 30 days, the volatility rate increased by 6.05%, as shares surge +0.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.34% upper at present.
During the last 5 trading sessions, ANAB rose by +16.10%, which changed the moving average for the period of 200-days by +22.49% in comparison to the 20-day moving average, which settled at $22.23. In addition, AnaptysBio Inc saw 15.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from Faga Daniel, who sale 3,000 shares at the price of $21.42 back on Mar 25 ’24. After this action, Faga Daniel now owns 749,087 shares of AnaptysBio Inc, valued at $64,268 using the latest closing price.
Faga Daniel, the CEO of AnaptysBio Inc, sale 145,940 shares at $22.78 during a trade that took place back on Mar 22 ’24, which means that Faga Daniel is holding 752,087 shares at $3,325,185 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -9.58 for the present operating margin
- 0.86 for the gross margin
The net margin for AnaptysBio Inc stands at -9.78. The total capital return value is set at -0.4. Equity return is now at value -93.44, with -30.79 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -9.09.
Currently, EBITDA for the company is -135.82 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 37.52. The receivables turnover for the company is 2.5for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.87.
Conclusion
In conclusion, AnaptysBio Inc (ANAB) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
